维普中文期刊产品整合服务
18篇 您的检索式:作者名="MYSLER E"
    题名 作者 年代 出处 被引量
1The apoptosis- 1/Fas protein in human systemic lupus erythematosus 显示文摘Mysler E Bini P Drappa J 1994J Clin Invest1994,93,3:1
2Canakinumab reducesthe risk of acute gouty arthritis flares during initiation ofallopurinol treatment: results of a double-blind,randomisedstudy 显示文摘Schlesinger N Mysler E Lin HY 2011Ann Rheum Dis2011,70,7:1
3Canakinumab reducesthe risk of acute gouty arthritis flares during initiation ofallopurinol treatment: results of a double-blind, randomisedstudy 显示文摘Schlesinger N Mysler E Lin HY 2011Arm Rheum Dis2011,70,7:1
4Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET),reduction in ulcer complications:randomised controlled trial显示文摘Schnitzer TJ Burmester GR Mysler E 2004Lancet2004,364,:1
5Canakinumab reduces therisk of acute gouty arthritis flares during initiation of allopurinol treat-ment: results of a double-blind, randomised study显示文摘Schlesinger N Mysler E Lin HY 2011Ann Rheum Dis2011,70,7:1
6Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications : randomised controlled trial显示文摘Schnitzer TJ Burmester GR Mysler E et al 2004Lancet2004,364,66:1
7Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study显示文摘Schlesinger N Mysler E Lin H Y 2011Ann Rheum Dis2011,70,12:1
8Theapoptosis-1/Fas protein in human systemic lupus erythematosus显示文摘Mysler E Bini P Drappa J 1994J ClinInvest1994,93,:1
9The apoptosis-1/Fas protein in human systemic lupus erythematosus 显示文摘Mysler E Koch N Mundel P 1994J Clin Invest1994,93,:1
10Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment:results of a double-blind,randomised study显示文摘Schlesinger N Mysler E Lin HY 2011Ann Rheum Dis2011,70,7:1
11The apoptosis-1/Fas protein in human systemic lupus erythematosus显示文摘Mysler E Bini P Drappa J 1994J Clin Invest1994,93,3:1
12Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TAR- GET), reduction in ulcer complications: randomised controlled trial显示文摘SCHNITZER TJ BURMESTER GR MYSLER E 2004Lancet2004,364,9435:1
13The apoptosis-1/Fas protein in human systemic lupus erythematosus显示文摘Mysler E Bini P Drappa J 1994J Clin Invest1994,93,3:1
14The apoptosis-1/Fas protein in human systemic lupusErythematosus显示文摘Mysler E Bini P Drappa J 1994J Clin Invest1994,93,3:1
15Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET),reduction in ulcer complications:randomised controlled trial显示文摘SCHNITZER T J BURMESTER G R MYSLER E 2004Lancet2004,364,9435:1
16with naproxen and ibuprofen Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications : randomised controlled trial 显示文摘Schnitzer TJ Burmester Comparison of lumiracoxib in the Therapeutic GR Mysler E 2004Lancet2004,364,:1
17Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment:results of a double-blind,randomised study显示文摘Schlesinger N Mysler E Lin HY 2011Ann Rheum Dis2011,70,:1
18Canakinumab reduces therisk of acute gouty arthritis flares during initiation of allopurinoltreatment: results of a double-blind, randomised study显示文摘Schlesinger N Mysler E Lin HY 2011AnnRheum Dis2011,70,7:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费